


Cell Therapy Oncology Limited

**Accounts for the year ended 31 July 2019
together with the Directors' Report**

Registered Number: 10219539



Cell Therapy Oncology Limited

Directors' Report

The directors submit this report and accounts for the year ended 31 July 2019.

Activities


There were no trading activities during the year and the company made neither a profit nor a loss.

Directors

The following directors held office during the year and subsequently:

Mr Ajan Reginald
Celixir plc (appointed 15th January 2019)
Dr Lee Chapman (resigned 15th January 2019)
Mr David Preston (resigned 15th January 2019)
Dr Sabena Sultan (resigned 15th January 2019)

Signed on behalf of the Board of Directors

A handwritten signature in black ink, appearing to be 'Ajan Reginald', with a long horizontal flourish extending to the right.

Mr Ajan Reginald
Director
2nd April 2020

Registered Office: Celixir House, Innovation Way, Stratford-upon-Avon, CV37 7GZ

Statement of Financial Position

As at:		31 July 2019	31 July 2018
	Notes	£	£
Non-current assets			
Intangible assets	4	10,075	10,075
Current assets			
Amounts owed by Group undertakings	5	1	1
Total assets		<u>10,076</u>	<u>10,076</u>
Current liabilities			
Amounts owed to Group undertakings	6	(184,979)	(184,979)
Total liabilities		<u>(184,979)</u>	<u>(184,979)</u>
Net liabilities		<u>(174,903)</u>	<u>(174,903)</u>
Capital and reserves			
Called up share capital	7	1	1
Share premium		-	-
Accumulated loss		(174,904)	(174,904)
Total Equity		<u>(174,903)</u>	<u>(174,903)</u>


The company did not trade during the year to 31 July 2019 or the period to 31 July 2018, and has made neither a profit nor a loss, nor any other recognised gain or loss.

For the year ending 31 July 2019 the company was entitled to exemption from audit under section 480 of the Companies Act 2006 relating to dormant companies.

The members have not required the company to obtain an audit of its accounts for the year in question in accordance with section 476.

The directors acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts.

The accounts were approved by the Director on 2nd April 2020.



Mr Ajan Reginald

Cell Therapy Oncology Limited

Notes to the Accounts

1. Accounting Policies

The accounts have been prepared under the historical cost convention and in accordance with applicable accounting standards.

2. Profit and Loss Account

No Statement of Profit and Loss has been prepared as the Company had no income or expenditure during the year to 31 July 2019 (period to 31 July 2018: nil).

3. Cash flow statement

The company has not prepared a cash flow statement as there have been no cash movements during the year.

4. Intangible assets

	Total £
Cost	
As at 31 July 2018 and 2019	<u>10,075</u>
Amortisation and impairment	
As at 31 July 2018 and 2019	<u>-</u>
Carrying amount as at 31 July 2018 and 2019	<u>10,075</u>

5. Trade and other receivables

	2019	2018
Due within one year:	£	£
Owed by Group undertakings	<u>1</u>	<u>1</u>
Total due within one year	<u>1</u>	<u>1</u>

6. Trade and other payables

	2019	2018
Due within one year:	£	£
Owed to Group undertakings	<u>184,979</u>	<u>184,979</u>
Total due within one year	<u>184,979</u>	<u>184,979</u>

The directors consider that the carrying amount of trade payables approximates to their fair value.

7. Called up share capital

Allotted, called up and fully paid:

	2019	2018
Number		
Ordinary shares of £1 each at start of year	1	1
Ordinary shares of £1 each allotted in the year	-	-
Ordinary shares of £1 each at end of year	<u>1</u>	<u>1</u>
	£	£
Ordinary shares of £1 each	<u>1</u>	<u>1</u>
	<u>1</u>	<u>1</u>

8. Ultimate Parent Company

The ultimate parent company is Celixir plc, registered in England & Wales. The consolidated accounts of that company are available to the public and may be obtained from Celixir House, Innovation Way, Stratford-Upon-Avon, CV37 7GZ.